Macrogen
마크로젠 · 038290
Industrials Commercial Services · KOSDAQ
Market cap US$96.5M (₩133.1B)
Overview
Macrogen reads and decodes genetic material, the DNA sequences of humans, animals, plants, viruses, and bacteria, and delivers the results as a service to researchers, clinicians, and other life-science users worldwide.
It operates genome-analysis centers in major cities across multiple countries, serving a global customer base. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company earns the large majority of its revenue from genomic sequencing services, with smaller contributions from oligonucleotide synthesis, microarray analysis, and genetically modified mouse production.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$96.2M
- FY2024US$98.4M
- FY2025US$141.5M
Operating profit
- FY2023−US$306.6K
- FY2024−US$4.7M
- FY2025US$131.2K
Net income
- FY2023−US$12.1M
- FY2024−US$5.6M
- FY2025−US$146.1K
Key ratios (FY2025)
Why it matters
Macrogen operates its genomic services through a network of genome-center locations in key cities around the world, giving it a direct international service footprint rather than relying solely on domestic operations.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?